Bariatric Surgery and Metabolic Dysfunction-Associated Fatty Liver Disease: a 2022 Update.
Praxis (Bern 1994)
; 112(2): 97-102, 2023 Feb.
Article
en En
| MEDLINE
| ID: mdl-36722105
ABSTRACT
Non-alcoholic fatty liver disease (NAFLD) has been recently termed metabolic dysfunction-associated fatty liver disease (MAFLD) to address the strong association with the metabolic syndrome. The prevalence of MAFLD is significantly increased in obese individuals and treatment of obesity is currently the cornerstone of management of MAFLD. Bariatric and metabolic surgery nowadays emerges as a key therapeutic strategy for the treatment of the MAFLD. This review aims to provide an update on the novel studies reporting the outcomes of bariatric surgery on the spectrum of MAFLD, from hepatic steatosis to cirrhosis.
Palabras clave
Leberzirrhose; Nicht-alkoholische Fettlebererkrankung; Non-alcoholic fatty liver disease; Stéatose hépatique non alcoolique; bariatric surgery; bariatrische Chirurgie; chirurgie bariatrique; cirrhose; cirrhosis; metabolic associated fatty liver disease; metabolisch assozierte Fettlebererkrankung; nicht-alkoholische Steatohepatitis; non-alcoholic steatohepatitis; stéatose hépatique métabolique
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Síndrome Metabólico
/
Cirugía Bariátrica
/
Enfermedad del Hígado Graso no Alcohólico
Tipo de estudio:
Diagnostic_studies
/
Risk_factors_studies
Límite:
Humans
Idioma:
En
Revista:
Praxis (Bern 1994)
Asunto de la revista:
MEDICINA
Año:
2023
Tipo del documento:
Article
País de afiliación:
Suiza